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Dehydroepiandrosterone and its sulfate (DHEAS) are sex hor-
mone precursors that exert marked neurotrophic and/or neu-
roprotective activity in the central nervous system. The
present study evaluated the effects of DHEAS and 17-estra-
diol (E2) in a focal cortical cold lesionmodel, in whichDHEAS
(50 mg/kg, sc) and E2 (35 mg/kg, sc) were administered either
as pretreatment (two subsequent injections 1 d and 1 h before
lesion induction) or posttreatment (immediately after lesion
induction). The focal cortical cold lesion was induced in the
primary motor cortex by means of a cooled copper cylinder
placed directly onto the cortical surface. One hour later, the
animals were killed, the brains cut into 0.4-mm-thick slices,
and the sections stained with 1% triphenyltetrazolium chlo-
ride. The volume of the hemispheric lesion was calculated for
each animal. The results demonstrated that the lesion area
was significantly attenuated in both the DHEAS- and E2- pre-
and posttreated groups and that in the presence of letrozole,
a nonsteroidal aromatase inhibitor, no neuroprotection was
observed, suggesting that the beneficial effect of DHEAS on
the cold injury might depend on the conversion of DHEAS to
E2 within the brain. It is concluded that even a single post-
traumatic administration of DHEAS may be of substantial
therapeutic benefit in the treatment of focal brain injurywith
vasogenic edema. (Endocrinology 147: 683–686, 2006)
ALTHOUGH DEHYDROEPIANDROSTERONE (DHEA)and its sulfate (DHEAS) are the most abundant prod-
ucts of the human adrenal cortex, until recently they were
regarded as relatively inert precursors of the sex steroids
estradiol (E2) and testosterone (1). Since the discovery of
neuroactive steroids (2), however, DHEA and DHEAS have
also been referred to as neurosteroids. The members of this
new family, which can be synthesized de novo in the nervous
system and which interact with different neurotransmitter
receptors, are primarily able to regulate glutamatergic and
GABAergic neurotransmission (3–5). Both DHEA and
DHEAS are abundant in the central nervous system (6) and
have been implicated as potential signaling molecules in the
neocortical organization during development, suggesting
that they might have neurotrophic activity or could promote
neuronal remodeling (3, 7).
Consistent with a neurotrophic role of these steroids,
DHEAS has been revealed to protect certain neuronal pop-
ulations against neurotoxic insults inflicted by the excitatory
amino acid glutamate (3, 7, 8). Because both DHEA and
DHEAS have widespread functions in the central nervous
system (9, 10), their therapeutic application may potentially
be beneficial in not only excitotoxicity-related diseases but
also other types of focal traumatic brain injury (11). Neuro-
active steroids (including E2 and its precursors DHEA and
DHEAS) have been evaluated as potential therapeutic agents
mostly in the form of pretreatment (12). Thus, mainly the
neuroprotective efficacy of neurosteroid administration dur-
ing the posttraumatic period remains to be elucidated, al-
though these data would be extremely important in clinical
practice (13). To address this issue, we used a well-estab-
lished animal model of traumatic brain injury, a focal cold
lesion (14), to examine the protective effects and potential
mechanisms of both pre- and posttraumatic DHEAS and E2
treatment in a morphological experiment.
Materials and Methods
Animals
YoungmaleWistar rats (n 55, 50–55 g, postnatal d 20–30)were kept
on a 12-h light, 12-h dark cycle and provided with unlimited access to
water and rat chow. All efforts were made to minimize the number of
animals used and their suffering. The principles of laboratory animal
care (National Institutes of Health publication no. 85–23) and the pro-
tocol for animal care approved by the Hungarian Health Committee
(1998) and the European Communities Council Directive of November
24, 1986 (86/609/EEC)were followed. The animalswere anesthetized ip,
using a mixture of Ketavet (100.0 mg/kg) and Rompun (xylazine, 8
mg/kg).
Cold lesion induction
The rats were fixed in a stereotaxic frame and a small hole was drilled
in the skull to access the primary motor cortex (MI), with its center 1.5
mm lateral and 1.5 mm rostral from the bregma. A copper cylinder (2
mm in diameter) cooled with a mixture of acetone and dry ice (78
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C) was used to produce a lesion in the MI. The cooling mixture was
continuously supplied for at least 15 min before application of the
cylinder to attain the maximal level of cold. The thermod was placed
onto the surface of the exposed cortex for 30 sec. Rectal temperature was
monitored and maintained at 37.0  0.5 C.
Histology
One hour after lesion induction, the animals were deeply anesthe-
tized and killed by decapitation. Thereafter, 0.4-mm-thick sliceswere cut
throughout the ischemic region with a vibratome (Campden Instru-
ments, Sileby, UK). The injury was visualized by using a 1% solution of
2,3,5-triphenyltetrazolium chloride (TTC; Sigma, Munich, Germany)
dissolved in artificial cerebrospinal fluid. When the reaction was com-
plete, the slices were fixed with 4% paraformaldehyde dissolved in 0.1
m phosphate buffer on coverslips for 15 min and subsequently kept
overnight in the same solution. Digital images of the stained slices were
capturedwith a scanner (Hewlett-Packard, PaloAlto, CA) at a resolution
of 1200 dpi (see Fig. 1B). The total surface area of the injured region on
each sectionwasmeasuredwithAdobe Photoshop software (version 8.0;
San Jose, CA). Then for each brain, the surface areas of the injured
regions from all sections were summed and multiplied by the slice
thickness (0.4 mm) to determine the total injured brain volume in cubic
millimeters. The data were further analyzed and displayed with Origin
(version 7.0; OriginLab Corp., Northampton, MA) and SPSS12 software
(Chicago, IL). The injured cortical volumes (mean  sem) within the
treatment groups were compared statistically by using one-way
ANOVA, followed by the Bonferroni test for the post hoc comparison of
the individual group means. A criterion of P 0.05 was adopted for the
statistical confidence.
Evans blue labeling
In another experiment (n  4 animals), Evans blue labeling was
performed as an alternative approach to control the extent of the lesion
extension and determine whether the cold lesion induced extravasation.
Then 2% Evans blue (0.2 ml; Sigma, St. Louis, MO) was injected into the
tail vein (iv) immediately after cold lesion induction. Thirty minutes
later, the animals were perfused transcardially with 4% paraformalde-
hyde dissolved in 0.1m phosphate buffer. The brains were removed and
postfixed overnight in the same fixative. Coronal sections (50 m thick)
encompassing the Evans blue-stained area were prepared with a vi-
bratome. The sections were then analyzed under an epifluorescent mi-
croscope (BX51; Olympus, Tokyo, Japan). Extravasated Evans blue was
localized at an excitation wavelength of 530–550 nm and an emission
wavelength of more than 590 nm.
Drug application
The control group (n 6) received only the DHEAS vehicle, distilled
water. DHEAS (50 mg/kg; Steraloids, Newport, RI) was administered
in distilled water sc (DHEAS-pretreated group, n  11) during the
evening of the preceding day, and subsequently 1 h before lesion in-
duction. The DHEAS-posttreated group (n 14) received the steroid in
the same concentration as a single sc injection immediately after lesion
induction. A study was also made of the effects of letrozole, a non-
steroidal aromatase inhibitor, on the action of DHEAS. The
letrozoleDHEAS group (n  5) received DHEAS in the same manner
as in the DHEAS-pretreated group, but letrozole (4 mg/kg dissolved in
paraffin oil) was administered sc 1 h before the steroid treatment. In the
E2-treated groups (Sigma, Munich, Germany), either pretreated (n  7)
or posttreated (n  8), the steroid was applied in the same manner as
described for the DHEAS animals. Then 35 mg/kg E2 dissolved in
sesame oil was administered, i.e. an amount equimolar with the dose of
DHEAS.
Results
Cortical lesion
Although a highly standardized cortical lesion was in-
duced within the MI region in the cortex, it did not result in
any significant change in the rectal temperature of the ani-
mals. Cold injury-induced brain trauma, a classical model of
vasogenic edema, is characterized by increased blood-brain
barrier (BBB) permeability, and this was clearly revealed by
the Evans blue labeling (Fig. 1A). Immediately after its iv
injection, Evans blue binds to serum albumin (15). In the
present study, the intravascular Evans blue was washed out
by the perfusion. Accordingly, the Evans blue fluorescence
observed in the brain parenchyma reflected the extravasated
and retained serum albumin, indicating the cortical area that
underwent severe damage during the cold injury induction.
Besides the primarily lesioned cortical tissue (above the
dashed line in Fig. 1A, this region appearing as the white area
after TTC labeling in Fig. 1B), additional Evans blue-positive
cells were detected in the perilesion rim. These cells fluo-
resced bright red.
DHEAS and E2 protect against cold lesion-induced injury
in vivo
Both DHEAS and E2, administered either before or after
cold lesion induction, led to a reduction in the volume of the
damaged cortical region (F5,45  6.145; P  0.001). Pretreat-
ment with DHEAS caused a significant decrease in the extent
of the infarct relative to the vehicle-treated controls (Fig. 2).
This protective effect of DHEAS pretreatment was com-
pletely blocked when the neurosteroid was administered
after letrozole. Surprisingly, DHEASwas evenmore effective
in diminishing the injured areawhen itwas administered just
after cold injury induction (Fig. 2). E2 treatment either before
or just after cold lesion induction resulted in a similar level
of protection to that observed with DHEAS (Fig. 2).
Discussion
In this study, we investigated the neuroprotective ability
ofDHEAS applied before or after cold lesion injury induction
and compared it with that of E2 treatment. The results clearly
demonstrate that both pre- and posttreatment with DHEAS
are effective in attenuating the brain injury. Our morpho-
metric analysis revealed that both pre- and posttreatment
with DHEAS result in a reduction in the infarcted area,
whereas the aromatase inhibitor letrozole abolish this
phenomenon.
FIG. 1. Representative photomicrographs of coronal sections of rats
with cold-induced lesions. A, Lesioned cortical area and affected cells
in the perilesion rimare visualized by fluorescentmicroscopy after the
iv injection of Evans blue. Scale bar, 0.5 mm. The black line denotes
the border between the lesioned tissue and the perilesion rim. B,
Lesioned area visualized with TTC. Photographic display of repre-
sentative brain sections are presented from control (a) and DHEAS-
posttreated animals (b). Note the decreased infarct size in the steroid-
administered slices (b). Scale bar, 5 mm.
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Recent studies (9, 10) demonstrated the neuroprotective
effect of DHEAS in different models, although cellular and
molecularmechanisms of this effect remain unclear. Lapchak
et al. (9) found that the -aminobutyric acid (GABA)A recep-
tor antagonist bicuculline abolishes the neuroprotective ef-
fect of DHEAS. This may be connected with the disturbed
calcium trafficking of injured neurons, which is an important
factor in the neurodegenerative process (16). The recent re-
sults of Kurata et al. (17) suggest that the inhibitory effects of
E2, DHEA, and DHEAS on the GABA-induced increases in
intracellular calcium concentrations differ and that DHEA
and DHEAS may act primarily at GABAA receptors rather
than at voltage-gated calcium channels. Rupprecht andHols-
boer (18) also concluded that DHEA and DHEAS are potent
allosteric modulators of the GABAA receptor function. Rac-
chi et al. (19) demonstrated that DHEA and other neuros-
teroids can regulate the neuronal function through their con-
current influence on transmitter-gated ion channels and gene
expression, and they postulated that DHEA can directly
modulate the age-associated impairment of protein kinase C
signal transduction. Another possible mechanism has been
proposed by Mao and Barger (7), who found that DHEAS
(but not DHEA) is able to elevate B-dependent transcription
factor activity, a phenomenon previously associated with
neuroprotection. Furthermore, steroids are known to exert
antiinflammatory effects by interaction with the immune
system, a possibility that cannot be ruled out in the present
experiments (20). Steroids also play a crucial role in the
development of the nervous system (21). As concerns our
own findings, it might be of particular importance that the
experiments were performed on young (2 to 3 wk old)
animals.
In contrast with the above-mentioned data, our results
demonstrate that letrozole, an aromatase inhibitor, is able to
block the neuroprotective effect of DHEAS. This raises the
question of whether DHEAS-triggered mechanisms are im-
plicated in the neuroprotective events in our model.
Our results with letrozole indicate that the administered
DHEAS was converted, partially or totally, to E2, which
seems to mediate the neuroprotective effect: E2 is also neu-
roprotective in the brain (22–25). The mechanisms underly-
ing this effect are not clear at present. However, a number of
authors have suggested that, among other actions, E2 exerts
its protective effect via mechanisms that attenuate apoptosis
but do not influence necrosis (26–28). Moreover, evidence is
accumulating that suggests that estrogen receptor-, rather
than estrogen receptor-, is the critical factor mediating the
protective effect (29, 30). Our results, together with the ob-
servations of Hajszan et al. (31), suggest that aromatic con-
version of DHEAS andDHEAoccurswithin the brain, which
opens up the possibility of its use in hormone replacement
therapy without incurring the known side effects associated
with systemic estrogen administration (32, 33). Maclusky et
al. (34) found that letrozole blocks DHEA-induced hip-
pocampal synaptogenesis only in females, whereas we ob-
served letrozole-dependent DHEAS neuroprotection against
focal cortical cold lesion induction in males. These results
suggest that the synaptogenetic and neuroprotective effects
of DHEA/DHEAS are regulated in different ways in the two
sexes, this phenomenon demanding further examination.
It seems particularly important that even a single post-
traumatic administration of DHEAS proved to be neuropro-
tective in our investigations. This is in good accordance with
the results of Lapchak et al. on an ischemic model (9). The
injury-induced vasogenic edema observed in our experi-
ments clearly indicates themalfunction of the BBB.However,
Evans blue not only leaks through the BBB butmay also enter
cells in the perilesion rim, the membrane of which may be
damaged in consequence of the cold lesion. It is important
that E2 induces endothelial nitrogen monoxide synthase-3
expression, which is essential for the protection of endothe-
lial cells (35). Hence, DHEAS treatmentmay contribute to the
maintenance of the BBB integrity (25) and probably the cell
membrane integrity, thereby protecting them from further
damage in the posttraumatic period. Another important is-
sue is the therapeutic window of DHEAS treatment. In our
experiments we used a postlesion time of 1 h, although this
time window might be longer: Yang et al. (13) reported that
E2 posttreatment is effective within 3 h after focal ischemia.
Despite the fact that the mechanisms have not yet been
elucidated, our observations clearly show that DHEAS is
neuroprotective when administered either before or after
trauma induction in our animal model of brain injury, the
extent of this protection being similar to that achieved with
E2. Nevertheless, it remains to be established whether a
similar effect can be detected in humans. These results sug-
gest that DHEAS may be of substantial therapeutic benefit
for the treatment of traumatic brain injury.
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